{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:22:27Z","timestamp":1785435747552,"version":"3.56.0"},"reference-count":148,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Development Plan Project of Jilin Province","award":["20250206029ZP"],"award-info":[{"award-number":["20250206029ZP"]}]},{"award":["20250206029ZP"],"award-info":[{"award-number":["20250206029ZP"]}],"id":[{"id":"https:\/\/ror.org\/049x38272","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Bladder cancer remains a major clinical challenge because of its high recurrence rate, marked molecular heterogeneity, frequent progression, and limited durability of current therapeutic strategies. Increasing evidence indicates that acetylation, as a reversible and druggable epigenetic modification, plays a central role in bladder cancer biology by linking chromatin remodeling to transcriptional regulation, DNA damage repair, metabolic adaptation, and immune modulation. Both histone and non-histone acetylation are frequently dysregulated in bladder cancer, and these alterations contribute to multiple malignant phenotypes, including sustained proliferation, defective cell-cycle control, apoptosis evasion, epithelial\u2013mesenchymal transition, metastatic progression, and therapeutic resistance. In this review, we summarize the mechanistic basis of acetylation imbalance in bladder cancer, with particular emphasis on the roles of histone acetyltransferases, histone deacetylases, sirtuins, and acetylation-associated metabolic regulators. We further discuss the emerging evidence that natural products can modulate acetylation-related pathways in bladder cancer, mainly through targeting HDAC-dependent histone deacetylation and SIRT1-associated non-histone deacetylation. Representative compounds, including sulforaphane, erucin, puerarin, capsaicin, curcumin, trichostatin A, trichostatin C, and pinocembrin, highlight the potential of natural products to suppress tumor growth, promote apoptosis, impair migration, and enhance antitumor immunity through acetylation-related mechanisms. Beyond summarizing individual agents, the evidence was evaluated based on the integration of acetylation-related target engagement, acetylation remodeling, and bladder cancer-relevant phenotypic outcomes. The current evidence is heterogeneous. SFN\/ECN, capsaicin, and pinocembrin offer the most convincing bladder cancer-specific support, whereas several other compounds remain limited by context-dependent effects, indirect pathway inference, or incomplete validation of the proposed acetylation mechanisms. These findings support an evidence-oriented translational framework that prioritizes natural products according to mechanistic robustness, bladder cancer specificity, and combination potential. Overall, acetylation-targeting natural products represent a promising but still evolving therapeutic strategy for bladder cancer, warranting further subtype-specific, mechanistically rigorous, and translationally oriented investigation.<\/jats:p>","DOI":"10.3390\/cimb48050489","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:11:13Z","timestamp":1778271073000},"page":"489","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives"],"prefix":"10.3390","volume":"48","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[{"name":"College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"},{"name":"Public Experimental Center, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"},{"name":"Public Experimental Center, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinzhamusu","family":"Yin","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Geng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"},{"name":"Public Experimental Center, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1449-2498","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117, China"},{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Changchun University of Chinese Medicine, Changchun 130117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/551S33a","article-title":"Bladder cancer","volume":"551","author":"Grayson","year":"2017","journal-title":"Nature"},{"key":"ref_2","first-page":"213","article-title":"Bladder cancer: An overview","volume":"38","author":"Whitmore","year":"1988","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Cookson","year":"2024","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer Epigenetics: From Mechanism to Therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.51.5.786","article-title":"Acetylation and methylation of histones and their possible role in the regulation of rna synthesis","volume":"51","author":"Allfrey","year":"1964","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bouyahya, A., Mechchate, H., Oumeslakht, L., Zeouk, I., Aboulaghras, S., Balahbib, A., Zengin, G., Kamal, M.A., Gallo, M., and Montesano, D. (2022). The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions. Biomolecules, 12.","DOI":"10.3390\/biom12030367"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sherif, Z.A., Ogunwobi, O.O., and Ressom, H.W. (2024). Mechanisms and technologies in cancer epigenetics. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1513654"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1289\/ehp.834943","article-title":"Acetylation, deacetylation and acyltransfer","volume":"49","author":"King","year":"1983","journal-title":"Environ. Health Perspect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s10020-023-00608-7","article-title":"Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation","volume":"29","author":"Luo","year":"2023","journal-title":"Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10295-015-1723-5","article-title":"Natural product discovery: Past, present, and future","volume":"43","author":"Katz","year":"2016","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","article-title":"Progress in research on paclitaxel and tumor immunotherapy","volume":"24","author":"Zhu","year":"2019","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/138945012802008973","article-title":"Discovery and mechanism of natural products as modulators of histone acetylation","volume":"13","author":"Salvador","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jprot.2016.10.003","article-title":"Lysine acetylation and cancer: A proteomics perspective","volume":"150","author":"Gil","year":"2017","journal-title":"J. Proteom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.30502","article-title":"Regulation of autophagy by protein methylation and acetylation in cancer","volume":"237","author":"Jeon","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bbagrm.2010.10.002","article-title":"Protein lysine acetylation in cellular function and its role in cancer manifestation","volume":"1799","author":"Arif","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)-Gene Regul. Mech."},{"key":"ref_20","first-page":"1061","article-title":"Oncogenes and tumor-suppressor genes in mesothelioma\u2014A synopsis","volume":"105","author":"Lechner","year":"1997","journal-title":"Environ. Health Perspect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1476-4598-12-96","article-title":"Histone acetyltransferase PCAF up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling","volume":"12","author":"Zheng","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.juro.2011.06.053","article-title":"Induction of caspase mediated apoptosis and down-regulation of nuclear factor-\u03baB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells","volume":"186","author":"Jeon","year":"2011","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13046-025-03585-3","article-title":"Histone deacetylase HDAC7 restricts CD8\u2009+\u2009T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: Reversal by pinocembrin","volume":"44","author":"Lv","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10826","DOI":"10.1128\/MCB.24.24.10826-10834.2004","article-title":"The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5\/PCAF and TIP60","volume":"24","author":"Patel","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11010-014-2036-0","article-title":"Human histone acetyltransferase 1 (Hat1) acetylates lysine 5 of histone H2A in vivo","volume":"392","author":"Tafrova","year":"2014","journal-title":"Mol. Cell Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13046-020-01783-9","article-title":"HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer","volume":"39","author":"Hu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16461","DOI":"10.18632\/oncotarget.3889","article-title":"By recruiting HDAC1, MORC2 suppresses p21 Waf1\/Cip1 in gastric cancer","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1038\/s41388-020-1337-x","article-title":"HDAC8 promotes the dissemination of breast cancer cells via AKT\/GSK-3\u03b2\/Snail signals","volume":"39","author":"An","year":"2020","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"59388","DOI":"10.18632\/oncotarget.10673","article-title":"HDAC10 promotes lung cancer proliferation via AKT phosphorylation","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/0008-5472.CAN-17-1388","article-title":"Histone Acetyltransferase KAT6A Upregulates PI3K\/AKT Signaling through TRIM24 Binding","volume":"77","author":"Lv","year":"2017","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Deng, Z., Sun, S., Xie, S., Jiang, M., Chen, B., Gu, C., and Yang, Y. (2022). NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.967811"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.18632\/oncotarget.7321","article-title":"SIRT1 at the crossroads of AKT1 and ER\u03b2 in malignant pleural mesothelioma cells","volume":"7","author":"Pinton","year":"2016","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.molcel.2006.11.021","article-title":"Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis","volume":"24","author":"Tang","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/carcin\/bgr292","article-title":"Activation of a Tip60\/E2F1\/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin","volume":"33","author":"Nissou","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eaaw8417","DOI":"10.1126\/sciadv.aaw8417","article-title":"PP2C\u03b4 inhibits p300-mediated p53 acetylation via ATM\/BRCA1 pathway to impede DNA damage response in breast cancer","volume":"5","author":"Li","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2402258","DOI":"10.1002\/advs.202402258","article-title":"Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53","volume":"12","author":"Gong","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X","article-title":"Histone acetylation and an epigenetic code","volume":"22","author":"Turner","year":"2000","journal-title":"BioEssays"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/epi.4.3.8484","article-title":"Histone acetylation: Where to go and how to get there","volume":"4","author":"MacDonald","year":"2009","journal-title":"Epigenetics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/PPO.0000000000000284","article-title":"Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer","volume":"23","author":"Benton","year":"2017","journal-title":"Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/PL00000896","article-title":"Histone acetylation and disease","volume":"58","author":"Timmermann","year":"2001","journal-title":"Cell Mol. Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13148-023-01615-5","article-title":"Histone acetylation: A key determinant of acquired cisplatin resistance in cancer","volume":"16","author":"Natu","year":"2024","journal-title":"Clin. Epigenet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4161\/cc.4.10.2113","article-title":"Towards the Human Cancer Epigenome: A First Draft of Histone Modifications","volume":"4","author":"Fraga","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/1541-7786.MCR-17-0260","article-title":"Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer","volume":"16","author":"Duex","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hoffmann, M.J., and Schulz, W.A. (2021). Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13236040"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1002\/cncr.28356","article-title":"Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma","volume":"119","author":"Chen","year":"2013","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/IGC.0b013e3181ae3efa","article-title":"The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical significance","volume":"20","author":"Zhen","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cellsig.2013.04.006","article-title":"Histone acetyltransferase hMOF promotes S phase entry and tumorigenesis in lung cancer","volume":"25","author":"Zhao","year":"2013","journal-title":"Cell Signal"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-32-8","article-title":"Epigenetic change in kidney tumor: Downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma","volume":"32","author":"Wang","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.23283","article-title":"The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma","volume":"122","author":"Pfister","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3892\/ijo.2014.2266","article-title":"Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma","volume":"44","author":"Cao","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4939-9434-2_17","article-title":"Functional Analysis of HDACs in Tumorigenesis","volume":"Volume 1983","author":"Hadley","year":"2019","journal-title":"Protein Acetylation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1007\/s13277-015-4618-1","article-title":"p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation","volume":"37","author":"Jia","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-025-03610-5","article-title":"HDAC2 as a therapeutic target in bladder cancer: Insights into the altered epigenetic regulation and lysine lactylation","volume":"45","author":"Xu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41419-024-07321-1","article-title":"Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells","volume":"15","author":"Cao","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1038\/s41467-024-49370-2","article-title":"Acetylation of histones and non-histone proteins is not a mere consequence of ongoing transcription","volume":"15","author":"Liebner","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41420-025-02410-2","article-title":"Functions and mechanisms of non-histone post-translational modifications in cancer progression","volume":"11","author":"Li","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.277.5325.567","article-title":"Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B","volume":"277","author":"Stokoe","year":"1997","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1126\/science.279.5351.710","article-title":"Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B","volume":"279","author":"Stephens","year":"1998","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/j.1460-2075.1994.tb06424.x","article-title":"Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1","volume":"13","author":"Alessi","year":"1994","journal-title":"EMBO J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M117.795955","article-title":"Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity","volume":"293","author":"Wu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"33156","DOI":"10.1074\/jbc.M113.472506","article-title":"Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration","volume":"288","author":"Williams","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2174\/1568026615666150825140822","article-title":"Role of Histone Acetylation in Cell Cycle Regulation","volume":"16","author":"Koprinarova","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1073\/pnas.91.9.3602","article-title":"p53 and E2F-1 cooperate to mediate apoptosis","volume":"91","author":"Wu","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/MCB.00552-08","article-title":"hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage","volume":"29","author":"Pediconi","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"194608","DOI":"10.1016\/j.bbagrm.2020.194608","article-title":"Non-histone protein acetylation by the evolutionarily conserved GCN5 and PCAF acetyltransferases","volume":"1864","author":"Downey","year":"2021","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Shan, X., Fu, Y.S., Aziz, F., Wang, X.Q., Yan, Q., and Liu, J.W. (2014). Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115401"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41467-025-57367-8","article-title":"HBV-associated hepatocellular carcinomas inhibit antitumor CD8(+) T cell via the long noncoding RNA HDAC2-AS2","volume":"16","author":"Gao","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/emboj\/19.4.662","article-title":"Regulation of E2F1 activity by acetylation","volume":"19","author":"Bauer","year":"2000","journal-title":"EMBO J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1038\/s41467-019-12861-8","article-title":"E2F1 acetylation directs p300\/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair","volume":"10","author":"Manickavinayaham","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"30830","DOI":"10.1074\/jbc.M402403200","article-title":"Specific role for p300\/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage","volume":"279","author":"Ianari","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/ncb998","article-title":"Differential regulation of E2F1 apoptotic target genes in response to DNA damage","volume":"5","author":"Pediconi","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.omto.2020.05.001","article-title":"Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149","volume":"17","author":"He","year":"2020","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-031-91459-1_2","article-title":"Acetylation-Mediated Epigenetic Consequences for Biological Control and Cancer","volume":"Volume 75","author":"Fritz","year":"2025","journal-title":"Histone and Non-Histone Reversible Acetylation in Development, Aging and Disease"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"55789","DOI":"10.18632\/oncotarget.10048","article-title":"The multifaceted role of lysine acetylation in cancer: Prognostic biomarker and therapeutic target","volume":"7","author":"Trisciuoglio","year":"2016","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2310146","DOI":"10.1002\/advs.202310146","article-title":"Targeting the KAT8\/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer","volume":"11","author":"Xie","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_79","first-page":"819","article-title":"HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin","volume":"27","author":"Zuo","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1038\/s41388-021-01999-9","article-title":"SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis","volume":"40","author":"Tan","year":"2021","journal-title":"Oncogene"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Monteiro-Reis, S., Lameirinhas, A., Miranda-Gon\u00e7alves, V., Felizardo, D., Dias, P.C., Oliveira, J., Gra\u00e7a, I., Gon\u00e7alves, C.S., Costa, B.M., and Henrique, R. (2020). Sirtuins\u2019 Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion. Cancers, 12.","DOI":"10.3390\/cancers12051066"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.7150\/jca.95549","article-title":"ACAT1 promotes proliferation and metastasis of bladder cancer via AKT\/GSK3\u03b2\/c-Myc signaling pathway","volume":"15","author":"Wang","year":"2024","journal-title":"J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1038\/s41388-025-03474-1","article-title":"ACSL5 regulated acetyl-CoA to promote bladder cancer cellular senescence via 53BP1 acetylation","volume":"44","author":"Luo","year":"2025","journal-title":"Oncogene"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-023-01786-3","article-title":"Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer","volume":"10","author":"Nunes","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1016\/j.febslet.2013.10.023","article-title":"Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1","volume":"587","author":"Han","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cellsig.2016.11.002","article-title":"Class I histone deacetylases regulate p53\/NF-\u03baB crosstalk in cancer cells","volume":"29","author":"Beyer","year":"2017","journal-title":"Cell Signal"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1126\/science.1062374","article-title":"Duration of nuclear NF-kappaB action regulated by reversible acetylation","volume":"293","author":"Chen","year":"2001","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1742-1241.2004.00284.x","article-title":"Cell proliferation and cell cycle control: A mini review","volume":"58","author":"Golias","year":"2004","journal-title":"Int. J. Clin. Pract."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Sun, Y., Liu, Y., Ma, X., and Hu, H. (2021). The Influence of Cell Cycle Regulation on Chemotherapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136923"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1081-1206(10)63176-6","article-title":"Apoptosis","volume":"78","author":"Fleisher","year":"1997","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11912-022-01199-y","article-title":"Targeting Apoptosis in Cancer","volume":"24","author":"Singh","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"119504","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"key":"ref_95","first-page":"195","article-title":"Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1\/p53 pathway","volume":"17","author":"Ye","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cac2.12138","article-title":"EMT-associated microRNAs and their roles in cancer stemness and drug resistance","volume":"41","author":"Pan","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41585-024-00963-y","article-title":"Metastasis development in non-muscle-invasive bladder cancer","volume":"22","author":"Leyderman","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"110357","DOI":"10.1016\/j.celrep.2022.110357","article-title":"Histone marks regulate the epithelial-to-mesenchymal transition via alternative splicing","volume":"38","author":"Segelle","year":"2022","journal-title":"Cell Rep."},{"key":"ref_99","first-page":"905","article-title":"Involvement of Bcl-2 family members, phosphatidylinositol 3\u2032-kinase\/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer","volume":"30","author":"Shankar","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/scd.2006.15.165","article-title":"Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells","volume":"15","author":"Kang","year":"2006","journal-title":"Stem Cells Dev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"116116","DOI":"10.1016\/j.ejmech.2023.116116","article-title":"Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer","volume":"266","author":"Lai","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"22207","DOI":"10.1002\/jcp.28788","article-title":"Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation","volume":"234","author":"Zhang","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cbi.2015.10.014","article-title":"Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells","volume":"242","author":"Liu","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00394-020-02227-y","article-title":"Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma","volume":"60","author":"Mitsiogianni","year":"2021","journal-title":"Eur. J. Nutr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jprot.2017.01.013","article-title":"The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer","volume":"156","author":"Abbaoui","year":"2017","journal-title":"J. Proteom."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1158\/0008-5472.CAN-08-2442","article-title":"Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation","volume":"69","author":"Choi","year":"2009","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"43806","DOI":"10.18632\/oncotarget.6245","article-title":"Inhibition of p300 lysine acetyltransferase activity by luteolin reduces tumor growth in head and neck squamous cell carcinoma (HNSCC) xenograft mouse model","volume":"6","author":"Selvi","year":"2015","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"167","DOI":"10.31083\/j.fbl2905167","article-title":"ARHGAP10, Transcriptionally Regulated by Sodium Butyrate, Promotes Ferroptosis of Ovarian Cancer Cells","volume":"29","author":"Ke","year":"2024","journal-title":"Front. Biosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"G482","DOI":"10.1152\/ajpgi.2001.280.3.G482","article-title":"Transient vs. prolonged histone hyperacetylation: Effects on colon cancer cell growth, differentiation, and apoptosis","volume":"280","author":"Wu","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_110","first-page":"8955","article-title":"Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: Possible selectivity on core binding factor-acute myeloid leukemia blasts","volume":"63","author":"Gozzini","year":"2003","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2015-0043","article-title":"Romidepsin for the Treatment of Peripheral T-Cell Lymphoma","volume":"20","author":"Iyer","year":"2015","journal-title":"Oncologist"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbrc.2013.05.102","article-title":"Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228","volume":"436","author":"Choudhary","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Merarchi, M., Sethi, G., Shanmugam, M.K., Fan, L., Arfuso, F., and Ahn, K.S. (2019). Role of Natural Products in Modulating Histone Deacetylases in Cancer. Molecules, 24.","DOI":"10.3390\/molecules24061047"},{"key":"ref_115","first-page":"1172","article-title":"Capsaicin attenuates cell migration via SIRT1 targeting and inhibition to enhance cortactin and \u03b2-catenin acetylation in bladder cancer cells","volume":"9","author":"Islam","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.canlet.2017.11.015","article-title":"TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPAR\u03b3-SIRT1 feedback loop in human bladder cancer cells","volume":"414","author":"Cao","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6374940","DOI":"10.1155\/2019\/6374940","article-title":"The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro","volume":"2019","author":"Roos","year":"2019","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Wang, C., Lei, L., Xu, Y., Li, Y., Zhang, J., Xu, Y., and Si, S. (2024). Trichostatin C Synergistically Interacts with DNMT Inhibitor to Induce Antineoplastic Effect via Inhibition of Axl in Bladder and Lung Cancer Cells. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040425"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3892\/or.2017.5795","article-title":"Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1-survivin downregulation at the late phase of treatment","volume":"38","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Lin, M.H., Lee, Y.H., Cheng, H.L., Chen, H.Y., Jhuang, F.H., and Chueh, P.J. (2016). Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1). Molecules, 21.","DOI":"10.3390\/molecules21070849"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/mnfr.201200276","article-title":"Inhibition of bladder cancer by broccoli isothiocyanates sulforaphane and erucin: Characterization, metabolism, and interconversion","volume":"56","author":"Abbaoui","year":"2012","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/BLC-160056","article-title":"The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer","volume":"2","author":"Douglass","year":"2016","journal-title":"Bladder Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Islam, A., Su, A.J., Zeng, Z.M., Chueh, P.J., and Lin, M.H. (2019). Capsaicin Targets tNOX (ENOX2) to Inhibit G1 Cyclin\/CDK Complex, as Assessed by the Cellular Thermal Shift Assay (CETSA). Cells, 8.","DOI":"10.3390\/cells8101275"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","article-title":"Romidepsin: A novel histone deacetylase inhibitor for cancer","volume":"20","author":"Bertino","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_126","first-page":"167","article-title":"Puerarin inhibits bladder cancer cell proliferation through the mTOR\/p70S6K signaling pathway","volume":"15","author":"Jiang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1442-2042.2006.01344.x","article-title":"Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest","volume":"13","author":"Li","year":"2006","journal-title":"Int. J. Urol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s10637-020-01038-6","article-title":"Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium\u2014An NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879","volume":"39","author":"Quinn","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S0007114512000657","article-title":"Organ-specific exposure and response to sulforaphane, a key chemopreventive ingredient in broccoli: Implications for cancer prevention","volume":"109","author":"Veeranki","year":"2013","journal-title":"Br. J. Nutr."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1158\/1078-0432.CCR-16-3250","article-title":"Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations","volume":"23","author":"Yao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-08-0024","article-title":"Phase II trial of curcumin in patients with advanced pancreatic cancer","volume":"14","author":"Dhillon","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical Toxicities of Histone Deacetylase Inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.25731","article-title":"Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial","volume":"56","author":"Le","year":"2012","journal-title":"Hepatology"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Sarfraz, M., Qamar, S., Rehman, M.U., Tahir, M.A., Ijaz, M., Ahsan, A., Asim, M.H., and Nazir, I. (2022). Nano-Formulation Based Intravesical Drug Delivery Systems: An Overview of Versatile Approaches to Improve Urinary Bladder Diseases. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091909"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12951-024-02816-7","article-title":"A mucoadhesive-to-penetrating nanomotors-in-hydrogel system for urothelium-oriented intravesical drug delivery","volume":"22","author":"Zheng","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acs.jnatprod.9b00949","article-title":"Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective","volume":"83","author":"Wu","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.yebeh.2015.07.028","article-title":"Botanicals as \u201cnew\u201d drugs: US development","volume":"52","author":"Hoffman","year":"2015","journal-title":"Epilepsy Behav."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1039\/b703830p","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"37","author":"Bieliauskas","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"105522","DOI":"10.1016\/j.jprot.2025.105522","article-title":"Expanding the landscape of lysine acetylation stoichiometry and clinical impact","volume":"321","author":"Gil","year":"2025","journal-title":"J. Proteom."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.mcpro.2022.100255","article-title":"In-depth Profiling and Quantification of the Lysine Acetylome in Hepatocellular Carcinoma with a Trapped Ion Mobility Mass Spectrometer","volume":"21","author":"Xu","year":"2022","journal-title":"Mol. Cell. Proteom."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Borcoman, E., Kamal, M., Marret, G., Dupain, C., Castel-Ajgal, Z., and Le Tourneau, C. (2021). HDAC Inhibition to Prime Immune Checkpoint Inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14010066"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1208\/s12249-013-9966-9","article-title":"Batch-to-batch quality consistency evaluation of botanical drug products using multivariate statistical analysis of the chromatographic fingerprint","volume":"14","author":"Xiong","year":"2013","journal-title":"Aaps Pharmscitech"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urolonc.2018.02.017","article-title":"The evolution of bladder cancer genomics: What have we learned and how can we use it?","volume":"36","author":"Audenet","year":"2018","journal-title":"Urol. Oncol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/5\/489\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:39:52Z","timestamp":1778837992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/5\/489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":148,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cimb48050489"],"URL":"https:\/\/doi.org\/10.3390\/cimb48050489","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}